

**PB 32 of 2024**

National Health (Minimum Stockholding) Amendment Determination (No. 3) 2024

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 27 March 2024

Nikolai Tsyganov

Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments commencing immediately after the commencement of Schedule 3 to the *National Health (Minimum Stockholding) Amendment Determination (No. 4) 2023* 2

National Health (Minimum Stockholding) Determination 2023 2

Schedule 2—Amendments commencing 1 April 2024 3

National Health (Minimum Stockholding) Determination 2023 3

1 Name

 (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 3) 2024*.

 (2) This instrument may also be cited as PB 32 of 2024.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 April 2024. | 1 April 2024 |
| 2. Schedule 1 | Immediately after the commencement of Schedule 3 to the *National Health (Minimum Stockholding) Amendment Determination (No. 4) 2023.* | 1 April 2024 |
| 3. Schedule 2 | 1 April 2024. | 1 April 2024 |

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

 This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing immediately after the commencement of Schedule 3 to the *National Health (Minimum Stockholding) Amendment Determination (No. 4) 2023*

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pregabalin | Capsule 150 mg | Oral | Pregabalin Lupin | 4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together |

2 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pregabalin | Capsule 75 mg | Oral | Pregabalin Lupin | 4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together |

Schedule 2—Amendments commencing 1 April 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Before:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Aripiprazole | Tablet 10 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Anastrozole | Tablet 1 mg | Oral | Arimidex | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |

2 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Bosentan | Tablet 125 mg (as monohydrate) | Oral | Bosentan Cipla | between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Bosentan | Tablet 125 mg (as monohydrate) | Oral | Tracleer | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |
| Bosentan | Tablet 62.5 mg (as monohydrate) | Oral | Tracleer | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |

3 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Calcium | Tablet, chewable, 500 mg (as carbonate) | Oral | Cal‑500 | after 30 November 2023—6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Candesartan | Tablet containing candesartan cilexetil 16 mg | Oral | NOUMED CANDESARTAN | between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 32 mg | Oral | NOUMED CANDESARTAN | between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 4 mg | Oral | NOUMED CANDESARTAN | between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 8 mg | Oral | NOUMED CANDESARTAN | between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand |

4 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Clarithromycin | Powder for oral liquid 250 mg per 5 mL, 50 mL | Oral | Klacid | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Clindamycin | Capsule 150 mg (as hydrochloride) | Oral | Clindamycin BNM | between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand |

5 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Diclofenac | Tablet (enteric coated) containing diclofenac sodium 50 mg | Oral | Fenac | between 1 March 2024 and 31 March 2024—0 months stock by reference to usual demand |

6 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Domperidone | Tablet 10 mg | Oral | Motilium | between 1 July 2023 and 31 March 2024—4 months stock by reference to usual PBS demand |

7 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Folinic acid | Injection containing calcium folinate equivalent to 100 mg folinic acid in 10 mL | Injection | Leucovorin Calcium (Pfizer Australia Pty Ltd) | between 1 March 2024 and 31 July 2024—0 months stock by reference to usual demand |

8 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Glimepiride | Tablet 1 mg | Oral | Aylide 1 | between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand |
| Glimepiride | Tablet 2 mg | Oral | Aylide 2 | between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand |
| Glimepiride | Tablet 3 mg | Oral | Aylide 3 | between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand |
| Glimepiride | Tablet 4 mg | Oral | Aylide 4 | between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand |

9 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Hydralazine | Tablet containing hydralazine hydrochloride 25 mg | Oral | Alphapress 25 | between 1 December 2023 and 31 March 2024—0 months stock by reference to usual PBS demand |

10 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Macrogol 3350 | Powder for oral solution 510 g | Oral | OsmoLax | between 1 November 2023 and 31 March 2024—4 months stock by reference to usual demand |

11 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Methoxyflurane | Liquid for inhalation 999 mg per g, 3 ml (with inhaler) | Inhalation by mouth | Penthrox | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Methylprednisolone | Injection containing methylprednisolone acetate 40 mg in 1 mL | Injection | Depo-Nisolone | between 1 April 2024 and 30 September 2024—4 months stock by reference to usual demand |

12 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Methylprednisolone | Powder for injection 40 mg (as sodium succinate) | Injection | Methylpred | between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand |

13 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Mycophenolic acid | Tablet containing mycophenolate mofetil 500 mg | Oral | CellCept | between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Mycophenolic acid | Tablet containing mycophenolate mofetil 500 mg | Oral | Noumed Mycophenolate | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |

14 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Oxybutynin | Tablet containing oxybutynin hydrochloride 5 mg | Oral | Ditropan | between 1 November 2023 and 31 March 2024—4 months stock by reference to usual demand |

15 Schedule 1 (table)

Before:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pregabalin | Capsule 150 mg | Oral | LYPRALIN | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | NOUMED PIOGLITAZONE | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |
| Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | Pioglitazone Sandoz | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |
| Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | NOUMED PIOGLITAZONE | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |
| Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | Pioglitazone Sandoz | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |

16 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Polyethylene glycol 400 with propylene glycol | Eye drops 4 mg‑3 mg per mL, 15 mL | Application to the Eye | Systane | between 1 July 2023 and 31 March 2024—4 months stock by reference to usual PBS demand |

17 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pregabalin | Capsule 25 mg | Oral | Pregabalin Lupin | 4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together |

18 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pregabalin | Capsule 300 mg | Oral | Pregabalin Lupin | 4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together |

19 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Prochlorperazine | Tablet containing prochlorperazine maleate 5 mg | Oral | Stemzine | between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand |

20 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ramipril with felodipine | Tablet 2.5 mg‑2.5 mg (modified release) | Oral | Triasyn 2.5/2.5 | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Riluzole | Oral suspension 50 mg per 10 mL, 300 mL | Oral | Teglutik | between 1 April 2024 and 30 September 2024—4 months stock by reference to usual demand |

21 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Risperidone | Tablet 1 mg | Oral | Risperidone generichealth | between 1 November 2023 and 31 March 2024—0 months stock by reference to usual demand |
| Risperidone | Tablet 2 mg | Oral | Risperidone generichealth | between 1 November 2023 and 31 March 2024—0 months stock by reference to usual demand |

22 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Risperidone | Tablet 3 mg | Oral | Risperidone generichealth | between 1 November 2023 and 31 March 2024—0 months stock by reference to usual demand |

23 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Risperidone | Tablet 4 mg | Oral | Risperidone generichealth | between 1 February 2024 and 30 April 2024—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Rosuvastatin | Tablet 10 mg (as calcium) | Oral | Noumed Rosuvastatin | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |
| Rosuvastatin | Tablet 20 mg (as calcium) | Oral | Noumed Rosuvastatin | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |
| Rosuvastatin | Tablet 40 mg (as calcium) | Oral | Noumed Rosuvastatin | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | Noumed Rosuvastatin | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |

24 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate | Enemas 3.125 g‑450 mg‑45 mg in 5 mL, 12 | Rectal | Micolette | between 1 November 2023 and 31 March 2024—4 months stock by reference to usual demand |

25 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Thiamine | Tablet containing thiamine hydrochloride 100 mg | Oral | Betavit | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tobramycin | Injection 80 mg (as sulfate) in 2 mL (without preservative) | Injection | Pfizer Australia Pty Ltd | between 1 April 2024 and 30 September 2024—4 months stock by reference to usual demand |

26 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Topiramate | Tablet 100 mg | Oral | APO‑Topiramate | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Topiramate | Tablet 100 mg | Oral | NOUMED TOPIRAMATE | between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand |

27 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Topiramate | Tablet 200 mg | Oral | APO‑Topiramate | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Topiramate | Tablet 200 mg | Oral | NOUMED TOPIRAMATE | between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand |

28 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Topiramate | Tablet 25 mg | Oral | APO‑Topiramate | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Topiramate | Tablet 25 mg | Oral | NOUMED TOPIRAMATE | between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand |

29 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Topiramate | Tablet 50 mg | Oral | APO‑Topiramate | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Topiramate | Tablet 50 mg | Oral | NOUMED TOPIRAMATE | between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand |

30 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tropisetron | I.V. injection 5 mg (as hydrochloride) in 5 mL | Injection | Tropisetron-AFT | between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand |

31 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Trimethoprim | Tablet 300 mg | Oral | Trimethoprim Viatris | after 30 April 2024—6 months stock by reference to usual demand of both Trimethoprim Viatris and Trimethoprim Mylan added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | NOUMED VALACICLOVIR | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |

32 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Vinorelbine | Solution for I.V. infusion 10 mg (as tartrate) in 1 mL | Injection | Navelbine | between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand |

33 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Voriconazole | Tablet 200 mg | Oral | Vfend | between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand |